BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA. 1999;281:1014-1018. [PMID: 10086436 DOI: 10.1001/jama.281.11.1014] [Cited by in Crossref: 314] [Cited by in F6Publishing: 235] [Article Influence: 14.3] [Reference Citation Analysis]
Number Citing Articles
1 Linas BP, Wong AY, Freedberg KA, Horsburgh CR Jr. Priorities for screening and treatment of latent tuberculosis infection in the United States. Am J Respir Crit Care Med 2011;184:590-601. [PMID: 21562129 DOI: 10.1164/rccm.201101-0181OC] [Cited by in Crossref: 100] [Cited by in F6Publishing: 45] [Article Influence: 10.0] [Reference Citation Analysis]
2 Dorjee K, Topgyal S, Dorjee C, Tsundue T, Namdol T, Tsewang T, Nangsel T, Lhadon D, Choetso T, Dawa T, Phentok T, DeLuca AN, Tsering L, Phunkyi D, Sadutshang TD, J Bonomo E, Paster Z, Chaisson RE. High Prevalence of Active and Latent Tuberculosis in Children and Adolescents in Tibetan Schools in India: The Zero TB Kids Initiative in Tibetan Refugee Children. Clin Infect Dis 2019;69:760-8. [PMID: 30462191 DOI: 10.1093/cid/ciy987] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
3 Conde MB, Melo FA, Marques AM, Cardoso NC, Pinheiro VG, Dalcin Pde T, Machado Junior A, Lemos AC, Netto AR, Durovni B, Sant'Anna CC, Lima D, Capone D, Barreira D, Matos ED, Mello FC, David FC, Marsico G, Afiune JB, Silva JR, Jamal LF, Telles MA, Hirata MH, Dalcolmo MP, Rabahi MF, Cailleaux-Cesar M, Palaci M, Morrone N, Guerra RL, Dietze R, Miranda SS, Cavalcante SC, Nogueira SA, Nonato TS, Martire T, Galesi VM, Dettoni Vdo V; BTA Committee on Tuberculosis., BTA Guidelines on Tuberculosis Work Group. III Brazilian Thoracic Association Guidelines on tuberculosis. J Bras Pneumol 2009;35:1018-48. [PMID: 19918635 DOI: 10.1590/s1806-37132009001000011] [Cited by in Crossref: 89] [Cited by in F6Publishing: 58] [Article Influence: 8.1] [Reference Citation Analysis]
4 Aouam K, Chaabane A, Loussaïef C, Ben Romdhane F, Boughattas N, Chakroun M. Les effets indésirables des antituberculeux: épidémiologie, mécanismes et conduite à tenir. Médecine et Maladies Infectieuses 2007;37:253-61. [DOI: 10.1016/j.medmal.2006.12.006] [Cited by in Crossref: 24] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
5 Fitzgerald DW, Sterling TR, Haas DW. Mycobacterium tuberculosis. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Elsevier; 2010. pp. 3129-63. [DOI: 10.1016/b978-0-443-06839-3.00250-2] [Cited by in Crossref: 19] [Article Influence: 1.7] [Reference Citation Analysis]
6 Assis DN, Navarro VJ. Human drug hepatotoxicity: a contemporary clinical perspective. Expert Opin Drug Metab Toxicol 2009;5:463-73. [PMID: 19416083 DOI: 10.1517/17425250902927386] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
7 Vinholt Schiødt F, Lee WM. Fulminant liver disease. Clinics in Liver Disease 2003;7:331-49. [DOI: 10.1016/s1089-3261(03)00026-6] [Cited by in Crossref: 46] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
8 Goletti D, Petrone L, Ippolito G, Niccoli L, Nannini C, Cantini F. Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs. Expert Rev Anti Infect Ther 2018;16:501-12. [PMID: 29848120 DOI: 10.1080/14787210.2018.1483238] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
9 Devarbhavi H. Adaptation and antituberculosis drug-induced liver injury. Am J Respir Crit Care Med 2012;186:387-8; author reply 388-9. [PMID: 22896595 DOI: 10.1164/ajrccm.186.4.387] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
10 Nolan CM. Isoniazid for latent tuberculosis infection: approaching 40 and reaching its prime. Am J Respir Crit Care Med 2003;168:412-3. [PMID: 12912731 DOI: 10.1164/rccm.2306004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
11 Campbell JR, Trajman A, Cook VJ, Johnston JC, Adjobimey M, Ruslami R, Eisenbeis L, Fregonese F, Valiquette C, Benedetti A, Menzies D. Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials. Lancet Infect Dis 2020;20:318-29. [PMID: 31866327 DOI: 10.1016/S1473-3099(19)30575-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
12 Fernández-Villar A, Sopeña B, Vázquez R, Ulloa F, Fluiters E, Mosteiro M, Martínez-Vázquez C, Piñeiro L. Isoniazid hepatotoxicity among drug users: the role of hepatitis C. Clin Infect Dis 2003;36:293-8. [PMID: 12539070 DOI: 10.1086/345906] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
13 Abboud G, Kaplowitz N. Drug-induced liver injury. Drug Saf. 2007;30:277-294. [PMID: 17408305 DOI: 10.2165/00002018-200730040-00001] [Cited by in Crossref: 197] [Cited by in F6Publishing: 158] [Article Influence: 14.1] [Reference Citation Analysis]
14 Viswanatha Swamy AH, Kulkarni RV, Thippeswamy AH, Koti BC, Gore A. Evaluation of hepatoprotective activity of Cissus quadrangularis stem extract against isoniazid-induced liver damage in rats. Indian J Pharmacol 2010;42:397-400. [PMID: 21189914 DOI: 10.4103/0253-7613.71920] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
15 Senousy BE, Belal SI, Draganov PV. Hepatotoxic effects of therapies for tuberculosis. Nat Rev Gastroenterol Hepatol. 2010;7:543-556. [PMID: 20808293 DOI: 10.1038/nrgastro.2010.134] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 3.8] [Reference Citation Analysis]
16 Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol. 2008;23:192-202. [PMID: 17995946 DOI: 10.1111/j.1440-1746.2007.05207.x] [Cited by in Crossref: 380] [Cited by in F6Publishing: 278] [Article Influence: 27.1] [Reference Citation Analysis]
17 Richardson RM. The diagnosis of tuberculosis in dialysis patients. Semin Dial 2012;25:419-22. [PMID: 22694662 DOI: 10.1111/j.1525-139X.2012.01093.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 6] [Article Influence: 2.6] [Reference Citation Analysis]
18 Cho YS, Jang TW, Kim HJ, Oh JY, Lee HK, Park HK, Ghim JL, Long NP, Park Y, Choi YK, Phuong NTT, Shin JG; Center for Personalized Precision Medicine of Tuberculosis. Isoniazid Population Pharmacokinetics and Dose Recommendation for Korean Patients With Tuberculosis Based on Target Attainment Analysis. J Clin Pharmacol 2021. [PMID: 34157153 DOI: 10.1002/jcph.1931] [Reference Citation Analysis]
19 Leeb S, Buxbaum C, Fischler B. Elevated transaminases are common in children on prophylactic treatment for tuberculosis. Acta Paediatr 2015;104:479-84. [DOI: 10.1111/apa.12908] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
20 Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS, Mayers DL. A Comprehensive Hepatic Safety Analysis of Nevirapine in Different Populations of HIV Infected Patients*: . JAIDS Journal of Acquired Immune Deficiency Syndromes 2003;34:S21-33. [DOI: 10.1097/00126334-200309011-00005] [Cited by in Crossref: 146] [Cited by in F6Publishing: 115] [Article Influence: 8.1] [Reference Citation Analysis]
21 Tweed CD, Wills GH, Crook AM, Dawson R, Diacon AH, Louw CE, McHugh TD, Mendel C, Meredith S, Mohapi L, Murphy ME, Murray S, Murthy S, Nunn AJ, Phillips PPJ, Singh K, Spigelman M, Gillespie SH. Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study. BMC Med 2018;16:46. [PMID: 29592805 DOI: 10.1186/s12916-018-1033-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 8.3] [Reference Citation Analysis]
22 Mori T, Leung CC. Tuberculosis in the global aging population. Infect Dis Clin North Am 2010;24:751-68. [PMID: 20674802 DOI: 10.1016/j.idc.2010.04.011] [Cited by in Crossref: 65] [Cited by in F6Publishing: 49] [Article Influence: 5.9] [Reference Citation Analysis]
23 Ramappa V, Aithal GP. Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management. J Clin Exp Hepatol. 2013;3:37-49. [PMID: 25755470 DOI: 10.1016/j.jceh.2012.12.001] [Cited by in Crossref: 180] [Cited by in F6Publishing: 123] [Article Influence: 20.0] [Reference Citation Analysis]
24 Adams PC, Arthur MJ, Boyer TD, DeLeve LD, Di Bisceglie AM, Hall M, Levin TR, Provenzale D, Seeff L. Screening in liver disease: report of an AASLD clinical workshop. Hepatology. 2004;39:1204-1212. [PMID: 15122748 DOI: 10.1002/hep.20169] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 2.4] [Reference Citation Analysis]
25 Wang P, Pradhan K, Zhong XB, Ma X. Isoniazid metabolism and hepatotoxicity. Acta Pharm Sin B. 2016;6:384-392. [PMID: 27709007 DOI: 10.1016/j.apsb.2016.07.014] [Cited by in Crossref: 93] [Cited by in F6Publishing: 52] [Article Influence: 18.6] [Reference Citation Analysis]
26 Indumathi CK, Sethuraman A, Jain S, Krishnamurthy S. Revised Antituberculosis Drug Doses and Hepatotoxicity in HIV Negative Children. Indian J Pediatr 2019;86:229-32. [PMID: 30515702 DOI: 10.1007/s12098-018-2812-z] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
27 Macaraig MM, Jalees M, Lam C, Burzynski J. Improved treatment completion with shorter treatment regimens for latent tuberculous infection. Int J Tuberc Lung Dis 2018;22:1344-9. [PMID: 30355415 DOI: 10.5588/ijtld.18.0035] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
28 Lewis JH. Drug-induced liver disease. Med Clin North Am. 2000;84:1275-1311, x. [PMID: 11026929 DOI: 10.1016/s0025-7125(05)70287-x] [Cited by in Crossref: 92] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
29 Lima Mde F, Melo HR. Hepatotoxicity induced by antituberculosis drugs among patients coinfected with HIV and tuberculosis. Cad Saude Publica. 2012;28:698-708. [PMID: 22488315 DOI: 10.1590/s0102-311x2012000400009] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
30 Diel R, Schaberg T, Loddenkemper R, Welte T, Nienhaus A. Enhanced cost-benefit analysis of strategies for LTBI screening and INH chemoprevention in Germany. Respir Med 2009;103:1838-53. [PMID: 19682884 DOI: 10.1016/j.rmed.2009.07.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
31 Sackoff JE, Pfeiffer MR, Driver CR, Streett LS, Munsiff SS, Dehovitz JA. Tuberculosis prevention for non–US-born pregnant women. American Journal of Obstetrics and Gynecology 2006;194:451-6. [DOI: 10.1016/j.ajog.2005.07.054] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
32 Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley CL, Desmond E, Keane J, Lewinsohn DA, Loeffler AM, Mazurek GH, O'Brien RJ, Pai M, Richeldi L, Salfinger M, Shinnick TM, Sterling TR, Warshauer DM, Woods GL. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis 2017;64:e1-e33. [PMID: 27932390 DOI: 10.1093/cid/ciw694] [Cited by in Crossref: 174] [Cited by in F6Publishing: 120] [Article Influence: 34.8] [Reference Citation Analysis]
33 Zevallos M, Justman JE. Tuberculosis in the elderly. Clin Geriatr Med 2003;19:121-38. [PMID: 12735118 DOI: 10.1016/s0749-0690(02)00057-5] [Cited by in Crossref: 53] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
34 Greenaway C, Sandoe A, Vissandjee B, Kitai I, Gruner D, Wobeser W, Pottie K, Ueffing E, Menzies D, Schwartzman K; Canadian Collaboration for Immigrant and Refugee Health. Tuberculosis: evidence review for newly arriving immigrants and refugees. CMAJ 2011;183:E939-51. [PMID: 20634392 DOI: 10.1503/cmaj.090302] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 4.6] [Reference Citation Analysis]
35 García-cortés M, Stephens C, Lucena MI, Fernández-castañer A, Andrade RJ. Causality assessment methods in drug induced liver injury: Strengths and weaknesses. Journal of Hepatology 2011;55:683-91. [DOI: 10.1016/j.jhep.2011.02.007] [Cited by in Crossref: 117] [Cited by in F6Publishing: 100] [Article Influence: 11.7] [Reference Citation Analysis]
36 Norton BL, Holland DP. Current management options for latent tuberculosis: a review. Infect Drug Resist 2012;5:163-73. [PMID: 23226700 DOI: 10.2147/IDR.S29180] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
37 Jafri SM, Singal AG, Kaul D, Fontana RJ. Detection and management of latent tuberculosis in liver transplant patients. Liver Transpl. 2011;17:306-314. [PMID: 21384513 DOI: 10.1002/lt.22203] [Cited by in Crossref: 42] [Cited by in F6Publishing: 30] [Article Influence: 4.2] [Reference Citation Analysis]
38 Tsai T, Ho V, Song M, Szapary P, Kato T, Wasfi Y, Li S, Shen Y, Leonardi C; on behalf of the PHOENIX 1, PHOENIX 2, ACCEPT, PEARL, Japanese Ustekinumab Study Groups. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection: Safety of ustekinumab in psoriasis patients with latent tuberculosis. British Journal of Dermatology 2012;167:1145-52. [DOI: 10.1111/j.1365-2133.2012.11142.x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 43] [Article Influence: 6.6] [Reference Citation Analysis]
39 Stine JG, Lewis JH. Hepatotoxicity of antibiotics: a review and update for the clinician. Clin Liver Dis. 2013;17:609-642, ix. [PMID: 24099021 DOI: 10.1016/j.cld.2013.07.008] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 3.1] [Reference Citation Analysis]
40 Dooley KE, Sterling TR. Treatment of Latent Tuberculosis Infection: Challenges and Prospects. Clinics in Chest Medicine 2005;26:313-26. [DOI: 10.1016/j.ccm.2005.02.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
41 Senior JR. Unintended hepatic adverse events associated with cancer chemotherapy. Toxicol Pathol 2010;38:142-7. [PMID: 19858501 DOI: 10.1177/0192623309351719] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
42 Shamseddeen H, Vilar-Gomez E, Chalasani N, Myers RP, Subramanian GM, Shlevin HH, Allgood AE, Orman ES. Spontaneous Fluctuations in Liver Biochemistries in Patients with Compensated NASH Cirrhosis: Implications for Drug Hepatotoxicity Monitoring. Drug Saf 2020;43:281-90. [PMID: 31907854 DOI: 10.1007/s40264-019-00896-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Bliven-Sizemore EE, Sterling TR, Shang N, Benator D, Schwartzman K, Reves R, Drobeniuc J, Bock N, Villarino ME; TB Trials Consortium. Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI. Int J Tuberc Lung Dis 2015;19:1039-44, i-v. [PMID: 26260821 DOI: 10.5588/ijtld.14.0829] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 7.6] [Reference Citation Analysis]
44 Lighter-fisher J, Surette A. Performance of an Interferon-Gamma Release Assay to Diagnose Latent Tuberculosis Infection During Pregnancy: . Obstetrics & Gynecology 2012;119:1088-95. [DOI: 10.1097/aog.0b013e3182546aff] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 2.1] [Reference Citation Analysis]
45 Tang P, Johnston J. Treatment of Latent Tuberculosis Infection. Curr Treat Options Infect Dis 2017;9:371-9. [PMID: 29238270 DOI: 10.1007/s40506-017-0135-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
46 Senior JR. Drug hepatotoxicity from a regulatory perspective. Clin Liver Dis 2007;11:507-24, vi. [PMID: 17723917 DOI: 10.1016/j.cld.2007.06.002] [Cited by in Crossref: 52] [Cited by in F6Publishing: 37] [Article Influence: 3.7] [Reference Citation Analysis]
47 Desrochers D, González-Peralta RP, McClenathan DT, Wilsey MJ Jr, Haafiz A. Isoniazid-induced severe hepatotoxicity: an infrequent but preventable cause of liver failure in children treated for latent tuberculosis infection. Clin Med Insights Pediatr 2011;5:9-13. [PMID: 23761995 DOI: 10.4137/CMPed.S6406] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
48 Yamada S, Tang M, Richardson K, Halaschek-Wiener J, Chan M, Cook VJ, Fitzgerald JM, Elwood RK, Brooks-Wilson A, Marra F. Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population. Pharmacogenomics 2009;10:1433-45. [PMID: 19761367 DOI: 10.2217/pgs.09.66] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 3.8] [Reference Citation Analysis]
49 Si X, Jiang L, Wang X, Ding Y, Luo L. Determination of isoniazid content via cysteic acid/graphene modified glassy carbon electrode. Anal Methods 2015;7:793-8. [DOI: 10.1039/c4ay02013h] [Cited by in Crossref: 13] [Article Influence: 2.2] [Reference Citation Analysis]
50 Archibald LK, Quisling RG. Central Nervous System Infections. In: Layon AJ, Gabrielli A, Friedman WA, editors. Textbook of Neurointensive Care. London: Springer; 2013. pp. 427-517. [DOI: 10.1007/978-1-4471-5226-2_22] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
51 Zabana Y, Domènech E, San Román AL, Beltrán B, Cabriada JL, Saro C, Araméndiz R, Ginard D, Hinojosa J, Gisbert JP. Tuberculous chemoprophylaxis requirements and safety in inflammatory bowel disease patients prior to anti-TNF therapy. Inflamm Bowel Dis. 2008;14:1387-1391. [PMID: 18452206 DOI: 10.1002/ibd.20496] [Cited by in Crossref: 36] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
52 Osmon DR. Antimicrobial Prophylaxis in Adults. Mayo Clinic Proceedings 2000;75:98-109. [DOI: 10.4065/75.1.98] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
53 . Documento de Consenso sobre tratamientos directamente observados en tuberculosis. Medicina Clínica 2000;115:749-57. [DOI: 10.1016/s0025-7753(00)71680-0] [Cited by in Crossref: 19] [Article Influence: 0.9] [Reference Citation Analysis]
54 Mir Viladrich I, Daudén Tello E, Solano-López G, López Longo FJ, Taxonera Samso C, Sánchez Martínez P, Martínez Lacasa X, García Gasalla M, Dorca Sargatal J, Arias-Guillén M, García García JM. Consensus Document on Prevention and Treatment of Tuberculosis in Patients for Biological Treatment. Arch Bronconeumol 2016;52:36-45. [PMID: 26187708 DOI: 10.1016/j.arbres.2015.04.016] [Cited by in Crossref: 27] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
55 Heard K, Green JL, Anderson V, Bucher-Bartelson B, Dart RC. A randomized, placebo-controlled trial to determine the course of aminotransferase elevation during prolonged acetaminophen administration. BMC Pharmacol Toxicol 2014;15:39. [PMID: 25047090 DOI: 10.1186/2050-6511-15-39] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
56 Sharma S, Singh A. Phenothiazines as anti-tubercular agents: mechanistic insights and clinical implications. Expert Opin Investig Drugs 2011;20:1665-76. [PMID: 22014039 DOI: 10.1517/13543784.2011.628657] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
57 Singh AK, Verma S, Kumar-M P, Soni H, Sharma S, Patil A, Sharma V. Appropriate chemopreventive strategy for anti-tubercular therapy related liver injury is unsettled: Results from a systematic review and network meta-analysis.Expert Rev Clin Pharmacol. 2020;13:1253-1262. [PMID: 33043729 DOI: 10.1080/17512433.2020.1835468] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
58 Cojutti P, Duranti S, Isola M, Baraldo M, Viale P, Bassetti M, Pea F. Might isoniazid plasma exposure be a valuable predictor of drug-related hepatotoxicity risk among adult patients with TB? J Antimicrob Chemother 2016;71:1323-9. [PMID: 26832752 DOI: 10.1093/jac/dkv490] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
59 Hayashi PH, Fontana RJ, Chalasani NP, Stolz AA, Talwalkar JA, Navarro VJ, Lee WM, Davern TJ, Kleiner DE, Gu J, Hoofnagle JH; US Drug-Induced Liver Injury Network Investigators. Under-reporting and Poor Adherence to Monitoring Guidelines for Severe Cases of Isoniazid Hepatotoxicity. Clin Gastroenterol Hepatol 2015;13:1676-82.e1. [PMID: 25724701 DOI: 10.1016/j.cgh.2015.02.024] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
60 Verma S, Kaplowitz N. Hepatotoxicity of Antitubercular Drugs. Drug-Induced Liver Disease. Elsevier; 2013. pp. 483-504. [DOI: 10.1016/b978-0-12-387817-5.00027-3] [Cited by in Crossref: 4] [Article Influence: 0.5] [Reference Citation Analysis]
61 Benito N, Sued O, Moreno A, Pablo Horcajada J, Gonz??lez J, Navasa M, Rimola A. Diagnosis and treatment of latent tuberculosis infection in liver transplant recipients in an endemic area: . Transplantation 2002;74:1381-6. [DOI: 10.1097/00007890-200211270-00006] [Cited by in Crossref: 73] [Cited by in F6Publishing: 57] [Article Influence: 3.8] [Reference Citation Analysis]
62 McCarthy FP, Rowlands S, Giles M. Tuberculosis in pregnancy - case studies and a review of Australia's screening process. Aust N Z J Obstet Gynaecol 2006;46:451-5. [PMID: 16953862 DOI: 10.1111/j.1479-828X.2006.00633.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
63 Shin J, Hunt CM, Suzuki A, Papay JI, Beach KJ, Cheetham TC. Characterizing phenotypes and outcomes of drug-associated liver injury using electronic medical record data: DRUG-ASSOCIATED LIVER INJURY. Pharmacoepidemiol Drug Saf 2013;22:190-8. [DOI: 10.1002/pds.3388] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
64 Ralph AP, Kenangalem E, Waramori G, Pontororing GJ, Sandjaja, Tjitra E, Maguire GP, Kelly PM, Anstey NM. High morbidity during treatment and residual pulmonary disability in pulmonary tuberculosis: under-recognised phenomena. PLoS One 2013;8:e80302. [PMID: 24312209 DOI: 10.1371/journal.pone.0080302] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 5.3] [Reference Citation Analysis]
65 van der Have M, Oldenburg B, Fidder HH, Belderbos TD, Siersema PD, van Oijen MG. Optimizing screening for tuberculosis and hepatitis B prior to starting tumor necrosis factor-α inhibitors in Crohn's disease. Dig Dis Sci 2014;59:554-63. [PMID: 23949640 DOI: 10.1007/s10620-013-2820-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
66 Churchyard GJ, Scano F, Grant AD, Chaisson RE. Tuberculosis preventive therapy in the era of HIV infection: overview and research priorities. J Infect Dis 2007;196 Suppl 1:S52-62. [PMID: 17624827 DOI: 10.1086/518662] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 3.3] [Reference Citation Analysis]
67 Yoshioka H, Fukaya S, Onosaka S, Nonogaki T, Nagatsu A. Kampo formula "Hochu-ekki-to" suppressed carbon tetrachloride-induced hepatotoxicity in mice. Environ Health Prev Med 2016;21:579-84. [PMID: 27709423 DOI: 10.1007/s12199-016-0571-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
68 Lin PL, Dartois V, Johnston PJ, Janssen C, Via L, Goodwin MB, Klein E, Barry CE 3rd, Flynn JL. Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques. Proc Natl Acad Sci U S A 2012;109:14188-93. [PMID: 22826237 DOI: 10.1073/pnas.1121497109] [Cited by in Crossref: 82] [Cited by in F6Publishing: 72] [Article Influence: 9.1] [Reference Citation Analysis]
69 Roz˘manić V, Kilvain S, Ahel V, Banac S, Gazdik M. Pulmonary tuberculosis with gallbladder involvement: A review and case report. Pediatrics International 2001;43:511-3. [DOI: 10.1046/j.1442-200x.2001.01435.x] [Cited by in Crossref: 6] [Article Influence: 0.3] [Reference Citation Analysis]
70 Devarbhavi H, Singh R, Patil M, Sheth K, Adarsh CK, Balaraju G. Outcome and determinants of mortality in 269 patients with combination anti-tuberculosis drug-induced liver injury. J Gastroenterol Hepatol. 2013;28:161-167. [PMID: 23020522 DOI: 10.1111/j.1440-1746.2012.07279.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 35] [Article Influence: 5.9] [Reference Citation Analysis]
71 Bergeron KG, Bonebrake RG, Gray CJ. Tuberculosis in pregnancy: current recommendations for screening and treatment in the USA. Expert Review of Anti-infective Therapy 2014;2:589-98. [DOI: 10.1586/14787210.2.4.589] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
72 Wallis RS, Johnson JL. Adult tuberculosis in the 21st century: pathogenesis, clinical features, and management: . Current Opinion in Pulmonary Medicine 2001;7:124-32. [DOI: 10.1097/00063198-200105000-00003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
73 Scholten JN, Driver CR, Munsiff SS, Kaye K, Rubino MA, Gourevitch MN, Trim C, Amofa J, Seewald R, Highley E, Fujiwara PI. Effectiveness of isoniazid treatment for latent tuberculosis infection among human immunodeficiency virus (HIV)-infected and HIV-uninfected injection drug users in methadone programs. Clin Infect Dis 2003;37:1686-92. [PMID: 14689352 DOI: 10.1086/379513] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
74 Gray EL, Goldberg HF. Baseline abnormal liver function tests are more important than age in the development of isoniazid-induced hepatoxicity for patients receiving preventive therapy for latent tuberculosis infection. Intern Med J 2016;46:281-7. [PMID: 26648478 DOI: 10.1111/imj.12979] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
75 Hosford JD, von Fricken ME, Lauzardo M, Chang M, Dai Y, Lyon JA, Shuster J, Fennelly KP. Hepatotoxicity from antituberculous therapy in the elderly: a systematic review. Tuberculosis (Edinb). 2015;95:112-122. [PMID: 25595441 DOI: 10.1016/j.tube.2014.10.006] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.1] [Reference Citation Analysis]
76 Thiim M, Friedman LS. Hepatotoxicity of antibiotics and antifungals. Clin Liver Dis 2003;7:381-99, vi-vii. [PMID: 12879990 DOI: 10.1016/s1089-3261(03)00021-7] [Cited by in Crossref: 42] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
77 Nguyen MH, Garcia G. Does isoniazid cause more serious hepatotoxicity in hepatitis B virus carriers? Am J Gastroenterology 2002;97:1092-3. [DOI: 10.1111/j.1572-0241.2002.05700.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
78 Padmapriyadarsini C, Sekar L, Reddy D, Chitra A, Poornagangadevi N, Selvaraj M, Bhavani PK, Mothi SN, Nandagopal K, Vennila S, Tamizhselvan M, Maheshmanisha J, Agarwal U, Rewari BB, Swaminathan S. Effectiveness of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected adults in programme setting. Indian J Med Res 2020;152:648-55. [PMID: 34145105 DOI: 10.4103/ijmr.IJMR_1582_18] [Reference Citation Analysis]
79 British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 2005;60:800-5. [PMID: 16055611 DOI: 10.1136/thx.2005.046797] [Cited by in Crossref: 316] [Cited by in F6Publishing: 227] [Article Influence: 19.8] [Reference Citation Analysis]
80 Jahng AW, Tran T, Bui L, Joyner JL. Safety of Treatment of Latent Tuberculosis Infection in Compensated Cirrhotic Patients During Transplant Candidacy Period. Transplantation 2007;83:1557-62. [DOI: 10.1097/01.tp.0000266578.45634.4f] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 3.6] [Reference Citation Analysis]
81 Li J, Munsiff SS, Agerton TB. Prevalence of Tuberculin Skin Test Positivity in Clinical Population in New York City. J Immigrant Minority Health 2010;12:816-22. [DOI: 10.1007/s10903-008-9204-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
82 Reichman LB, Lardizabal A, Hayden CH. Considering the Role of Four Months of Rifampin in the Treatment of Latent Tuberculosis Infection. Am J Respir Crit Care Med 2004;170:832-5. [DOI: 10.1164/rccm.200405-584pp] [Cited by in Crossref: 38] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
83 Menzies D, Dion MJ, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med 2004;170:445-9. [PMID: 15172892 DOI: 10.1164/rccm.200404-478OC] [Cited by in Crossref: 102] [Cited by in F6Publishing: 38] [Article Influence: 6.0] [Reference Citation Analysis]
84 Peter Ormerod L. Assessing risk and managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNFα treatment. Cytokine 2004;28:179-81. [DOI: 10.1016/j.cyto.2004.07.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
85 Tost JR, Vidal R, Maldonado J, Caylà JA. Efectividad y tolerancia de las pautas de tratamiento antituberculoso sin isoniacida y/o rifampicina. Análisis de 85 casos. Archivos de Bronconeumología 2008;44:478-83. [DOI: 10.1016/s0300-2896(08)72117-3] [Cited by in Crossref: 9] [Article Influence: 0.7] [Reference Citation Analysis]
86 Gray D, Nuttall J, Lombard C, Davies M, Workman L, Apolles P, Eley B, Cotton M, Zar H. Low Rates of Hepatotoxicity in HIV-infected Children on Anti-retroviral Therapy with and without Isoniazid Prophylaxis. Journal of Tropical Pediatrics 2010;56:159-65. [DOI: 10.1093/tropej/fmp079] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
87 Rieder H. Risk of Travel‐Associated Tuberculosis. CLIN INFECT DIS 2001;33:1393-6. [DOI: 10.1086/323127] [Cited by in Crossref: 45] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
88 Winthrop KL. Update on tuberculosis and other opportunistic infections associated with drugs blocking tumour necrosis factor {alpha}. Ann Rheum Dis 2005;64 Suppl 4:iv29-30. [PMID: 16239382 DOI: 10.1136/ard.2005.042390] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
89 van Hest R, Baars H, Kik S, van Gerven P, Trompenaars MC, Kalisvaart N, Keizer S, Borgdorff M, Mensen M, Cobelens F. Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment. Clin Infect Dis. 2004;39:488-496. [PMID: 15356811 DOI: 10.1086/422645] [Cited by in Crossref: 70] [Cited by in F6Publishing: 60] [Article Influence: 4.1] [Reference Citation Analysis]
90 Efferen LS. Tuberculosis and pregnancy: . Current Opinion in Pulmonary Medicine 2007;13:205-11. [DOI: 10.1097/mcp.0b013e3280f6ceee] [Cited by in Crossref: 19] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
91 Mosimaneotsile B, Mathoma A, Chengeta B, Nyirenda S, Agizew TB, Tedla Z, Motsamai OI, Kilmarx PH, Wells CD, Samandari T. Isoniazid tuberculosis preventive therapy in HIV-infected adults accessing antiretroviral therapy: a Botswana Experience, 2004-2006. J Acquir Immune Defic Syndr 2010;54:71-7. [PMID: 19934764 DOI: 10.1097/QAI.0b013e3181c3cbf0] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
92 Liang W, Ren H, Li Y, Qiu H, Ye BC. A robust electrochemical sensing based on bimetallic metal-organic framework mediated Mo2C for simultaneous determination of acetaminophen and isoniazid. Anal Chim Acta 2020;1136:99-105. [PMID: 33081955 DOI: 10.1016/j.aca.2020.08.044] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
93 Lange C, Mandalakas AM, Kalsdorf B, Denkinger CM, Sester M. Clinical Application of Interferon-γ Release Assays for the Prevention of Tuberculosis in Countries with Low Incidence. Pathog Immun 2016;1:308-29. [PMID: 28217762 DOI: 10.20411/pai.v1i2.173] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 2.6] [Reference Citation Analysis]
94 Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med. 2000;161:S221-S247. [PMID: 10764341 DOI: 10.1164/ajrccm.161.supplement_3.ats600] [Cited by in Crossref: 779] [Cited by in F6Publishing: 645] [Article Influence: 37.1] [Reference Citation Analysis]
95 Li X, Peterson YK, Inks ES, Himes RA, Li J, Zhang Y, Kong X, Chou CJ. Class I HDAC Inhibitors Display Different Antitumor Mechanism in Leukemia and Prostatic Cancer Cells Depending on Their p53 Status. J Med Chem 2018;61:2589-603. [PMID: 29499113 DOI: 10.1021/acs.jmedchem.8b00136] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 8.7] [Reference Citation Analysis]
96 Chang AH, Polesky A, Bhatia G. House calls by community health workers and public health nurses to improve adherence to isoniazid monotherapy for latent tuberculosis infection: a retrospective study. BMC Public Health 2013;13:894. [PMID: 24073620 DOI: 10.1186/1471-2458-13-894] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
97 Tsai T, Ho J, Song M, Szapary P, Guzzo C, Shen Y, Li S, Kim K, Kim T, Choi J, Youn J. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: A phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). Journal of Dermatological Science 2011;63:154-63. [DOI: 10.1016/j.jdermsci.2011.05.005] [Cited by in Crossref: 139] [Cited by in F6Publishing: 109] [Article Influence: 13.9] [Reference Citation Analysis]
98 Sahbazian B, Weis SE. Treatment of Active Tuberculosis: Challenges and Prospects. Clinics in Chest Medicine 2005;26:273-82. [DOI: 10.1016/j.ccm.2005.02.011] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
99 Denholm JT, McBryde ES. The use of anti-tuberculosis therapy for latent TB infection. Infect Drug Resist 2010;3:63-72. [PMID: 21694895 DOI: 10.2147/idr.s8994] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
100 Blumberg HM. Treatment of Latent Tuberculosis Infection: Back to the Beginning. Clinical Infectious Diseases 2004;39:1772-5. [DOI: 10.1086/425620] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
101 Tedla Z, Nyirenda S, Peeler C, Agizew T, Sibanda T, Motsamai O, Vernon A, Wells CD, Samandari T. Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in Botswana. Am J Respir Crit Care Med. 2010;182:278-285. [PMID: 20378730 DOI: 10.1164/rccm.200911-1783oc] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
102 Zhou S, Chan E, Duan W, Huang M, Chen YZ. Drug bioactivation, covalent binding to target proteins and toxicity relevance. Drug Metab Rev 2005;37:41-213. [PMID: 15747500 DOI: 10.1081/dmr-200028812] [Cited by in Crossref: 168] [Cited by in F6Publishing: 27] [Article Influence: 10.5] [Reference Citation Analysis]
103 Grant AD, Mngadi KT, van Halsema CL, Luttig MM, Fielding KL, Churchyard GJ. Adverse events with isoniazid preventive therapy: experience from a large trial. AIDS 2010;24:S29-36. [DOI: 10.1097/01.aids.0000391019.10661.66] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
104 Smith BM, Schwartzman K, Bartlett G, Menzies D. Adverse events associated with treatment of latent tuberculosis in the general population. CMAJ 2011;183:E173-9. [PMID: 21220436 DOI: 10.1503/cmaj.091824] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
105 Cruz AT, Ahmed A, Mandalakas AM, Starke JR. Treatment of Latent Tuberculosis Infection in Children. J Pediatric Infect Dis Soc 2013;2:248-58. [PMID: 26619479 DOI: 10.1093/jpids/pit030] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
106 Abel L, Fellay J, Haas DW, Schurr E, Srikrishna G, Urbanowski M, Chaturvedi N, Srinivasan S, Johnson DH, Bishai WR. Genetics of human susceptibility to active and latent tuberculosis: present knowledge and future perspectives. The Lancet Infectious Diseases 2018;18:e64-75. [DOI: 10.1016/s1473-3099(17)30623-0] [Cited by in Crossref: 66] [Cited by in F6Publishing: 32] [Article Influence: 22.0] [Reference Citation Analysis]
107 Gardiner SJ, Begg EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 2006;58:521-90. [PMID: 16968950 DOI: 10.1124/pr.58.3.6] [Cited by in Crossref: 258] [Cited by in F6Publishing: 158] [Article Influence: 17.2] [Reference Citation Analysis]
108 Tan M, Menzies D, Schwartzman K. Tuberculosis screening of travelers to higher-incidence countries: a cost-effectiveness analysis. BMC Public Health 2008;8:201. [PMID: 18534007 DOI: 10.1186/1471-2458-8-201] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
109 Donald PR. Antituberculosis drug-induced hepatotoxicity in children. Pediatr Rep. 2011;3:e16. [PMID: 21772953 DOI: 10.4081/pr.2011.e16] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 4.4] [Reference Citation Analysis]
110 Johnston VJ, Grant AD. Tuberculosis in travellers. Travel Med Infect Dis 2003;1:205-12. [PMID: 17291919 DOI: 10.1016/j.tmaid.2003.11.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
111 Kumar S, Kumar R, Dwivedi A, Pandey AK. In vitro antioxidant, antibacterial, and cytotoxic activity and in vivo effect of Syngonium podophyllum and Eichhornia crassipes leaf extracts on isoniazid induced oxidative stress and hepatic markers. Biomed Res Int. 2014;2014:459452. [PMID: 25162013 DOI: 10.1155/2014/459452] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
112 Johnson JL, Ellner JJ. Adult tuberculosis overview: African versus Western perspectives: . Current Opinion in Pulmonary Medicine 2000;6:180-6. [DOI: 10.1097/00063198-200005000-00003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
113 Teklay G, Teklu T, Legesse B, Tedla K, Klinkenberg E. Barriers in the implementation of isoniazid preventive therapy for people living with HIV in Northern Ethiopia: a mixed quantitative and qualitative study. BMC Public Health 2016;16:840. [PMID: 27543096 DOI: 10.1186/s12889-016-3525-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
114 Dobbs TE, Webb RM. Chemotherapy of Tuberculosis. Microbiol Spectr 2017;5. [PMID: 28387179 DOI: 10.1128/microbiolspec.TNMI7-0040-2017] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
115 Zhang Y, Jiang X, Zhang J, Zhang H, Li Y. Simultaneous voltammetric determination of acetaminophen and isoniazid using MXene modified screen-printed electrode. Biosensors and Bioelectronics 2019;130:315-21. [DOI: 10.1016/j.bios.2019.01.043] [Cited by in Crossref: 89] [Cited by in F6Publishing: 39] [Article Influence: 44.5] [Reference Citation Analysis]
116 Fábrega E, Sampedro B, Cabezas J, Casafont F, Mieses MÁ, Moraleja I, Crespo J, Pons-romero F. Chemoprophylaxis with isoniazid in liver transplant recipients. Liver Transpl 2012;18:1110-7. [DOI: 10.1002/lt.23480] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
117 Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med. 2003;167:1472-1477. [PMID: 12569078 DOI: 10.1164/rccm.200206-626oc] [Cited by in Crossref: 455] [Cited by in F6Publishing: 154] [Article Influence: 25.3] [Reference Citation Analysis]
118 Lobue P, Menzies D. Treatment of latent tuberculosis infection: An update: Treatment of latent TB infection. Respirology 2010;15:603-22. [DOI: 10.1111/j.1440-1843.2010.01751.x] [Cited by in Crossref: 127] [Cited by in F6Publishing: 88] [Article Influence: 11.5] [Reference Citation Analysis]
119 Hussaini SH, Farrington EA. Idiosyncratic drug-induced liver injury: an overview. Expert Opin Drug Saf. 2007;6:673-684. [PMID: 17967156 DOI: 10.1517/14740338.6.6.673] [Cited by in Crossref: 121] [Cited by in F6Publishing: 97] [Article Influence: 8.6] [Reference Citation Analysis]
120 Bourré-Tessier J, Arino-Torregrosa M, Choquette D. Increased incidence of liver enzymes abnormalities in patients treated with isoniazid in combination with disease modifying and/or biologic agents. Clin Rheumatol 2014;33:1049-53. [PMID: 24554383 DOI: 10.1007/s10067-014-2528-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
121 Marguet C, Gut-robert C, André M. Particularités du traitement de la tuberculose chez l’enfant. Revue des Maladies Respiratoires 2008;25:67-8. [DOI: 10.1016/s0761-8425(08)56025-6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
122 Schraufnagel DE. To eliminate tuberculosis, we must universally encourage treatment of its latent form. Respirology 2015;20:851-4. [PMID: 26172202 DOI: 10.1111/resp.12598] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
123 Piccini P, Chiappini E, Tortoli E, de Martino M, Galli L. Clinical peculiarities of tuberculosis. BMC Infect Dis 2014;14 Suppl 1:S4. [PMID: 24564419 DOI: 10.1186/1471-2334-14-S1-S4] [Cited by in Crossref: 34] [Cited by in F6Publishing: 10] [Article Influence: 4.9] [Reference Citation Analysis]
124 White MC, Tulsky JP, Lee JR, Chen L, Goldenson J, Spetz J, Kawamura LM. Isoniazid vs. rifampin for latent tuberculosis infection in jail inmates: toxicity and adherence. J Correct Health Care 2012;18:131-42. [PMID: 22419641 DOI: 10.1177/1078345811435973] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
125 Holty JE, Gould MK, Meinke L, Keeffe EB, Ruoss SJ. Tuberculosis in liver transplant recipients: a systematic review and meta-analysis of individual patient data. Liver Transpl. 2009;15:894-906. [PMID: 19642133 DOI: 10.1002/lt.21709] [Cited by in Crossref: 86] [Cited by in F6Publishing: 64] [Article Influence: 7.2] [Reference Citation Analysis]
126 Hazlewood GS, Naimark D, Gardam M, Bykerk V, Bombardier C. Prophylaxis for latent tuberculosis infection prior to anti–tumor necrosis factor therapy in low-risk elderly patients with rheumatoid arthritis: a decision analysis. Arthritis Care Res (Hoboken) 2013;65:1722-31. [PMID: 23836530 DOI: 10.1002/acr.22063] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 1.6] [Reference Citation Analysis]
127 Holland DP, Sanders GD, Hamilton CD, Stout JE. Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection. Am J Respir Crit Care Med 2009;179:1055-60. [PMID: 19299495 DOI: 10.1164/rccm.200901-0153OC] [Cited by in Crossref: 57] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
128 Russom M, Debesai M, Zeregabr M, Berhane A, Tekeste T, Teklesenbet T. Serious hepatotoxicity following use of isoniazid preventive therapy in HIV patients in Eritrea. Pharmacol Res Perspect 2018;6:e00423. [PMID: 30073087 DOI: 10.1002/prp2.423] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
129 Berg J, Blumberg EJ, Sipan CL, Friedman LS, Kelley NJ, Vera AY, Hofstetter CR, Hovell MF. Somatic complaints and isoniazid (INH) side effects in Latino adolescents with latent tuberculosis infection (LTBI). Patient Educ Couns 2004;52:31-9. [PMID: 14729288 DOI: 10.1016/s0738-3991(02)00268-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
130 Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, Fujiwara P, Grzemska M, Hopewell PC, Iseman MD, Jasmer RM, Koppaka V, Menzies RI, O'Brien RJ, Reves RR, Reichman LB, Simone PM, Starke JR, Vernon AA; American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-62. [PMID: 12588714 DOI: 10.1164/rccm.167.4.603] [Cited by in Crossref: 1299] [Cited by in F6Publishing: 885] [Article Influence: 72.2] [Reference Citation Analysis]
131 Kramer O, Albrecht J. Clinical presentation of terbinafine‐induced severe liver injury and the value of laboratory monitoring: a Critically Appraised Topic. Br J Dermatol 2017;177:1279-84. [DOI: 10.1111/bjd.15854] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
132 Dodani SK, Nasim A, Aziz T, Naqvi A. The efficacy of isoniazid prophylaxis in renal transplant recipients in a high tuberculosis burden country. Transpl Infect Dis 2021;:e13709. [PMID: 34331355 DOI: 10.1111/tid.13709] [Reference Citation Analysis]
133 Pettit AC, Bethel J, Hirsch-Moverman Y, Colson PW, Sterling TR; Tuberculosis Epidemiologic Studies Consortium. Female sex and discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis. J Infect 2013;67:424-32. [PMID: 23845828 DOI: 10.1016/j.jinf.2013.07.015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
134 Chang SH, Nahid P, Eitzman SR. Hepatotoxicity in Children Receiving Isoniazid Therapy for Latent Tuberculosis Infection. J Pediatric Infect Dis Soc 2014;3:221-7. [PMID: 26625385 DOI: 10.1093/jpids/pit089] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
135 Moon HH, Park SY, Kim JM, Park JB, Kwon CHD, Peck KR, Kim SJ, Lee SK, Joh JW. Isoniazid Prophylaxis for Latent Tuberculosis Infections in Liver Transplant Recipients in a Tuberculosis-Endemic Area. Ann Transplant. 2017;22:338-345. [PMID: 28579606 DOI: 10.12659/aot.902989] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
136 Bracchi M, van Halsema C, Post F, Awosusi F, Barbour A, Bradley S, Coyne K, Dixon-Williams E, Freedman A, Jelliman P, Khoo S, Leen C, Lipman M, Lucas S, Miller R, Seden K, Pozniak A. British HIV Association guidelines for the management of tuberculosis in adults living with HIV 2019. HIV Med 2019;20 Suppl 6:s2-s83. [PMID: 31152481 DOI: 10.1111/hiv.12748] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
137 Chaisson RE. Tuberculosis Chemotherapy: Still a Double-edged Sword. Am J Respir Crit Care Med 2003;167:1461-2. [DOI: 10.1164/rccm.2303004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
138 Kraut A, Coodin M, Plessis R, Mclean D. Predictors of Positive Tuberculin Skin Test (TST) Results after 2‐Step TST among Health Care Workers in Manitoba, Canada. CLIN INFECT DIS 2004;39:e113-8. [DOI: 10.1086/425916] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
139 Moonan PK, Nair SA, Agarwal R, Chadha VK, Dewan PK, Gupta UD, Ho CS, Holtz TH, Kumar AM, Kumar N, Kumar P, Maloney SA, Mase SR, Oeltmann JE, Paramasivan CN, Parmar MM, Rade KK, Ramachandran R, Rao R, Salhorta VS, Sarin R, Sarin S, Sachdeva KS, Selvaraju S, Singla R, Surie D, Tonsing J, Tripathy SP, Khaparde SD. Tuberculosis preventive treatment: the next chapter of tuberculosis elimination in India. BMJ Glob Health 2018;3:e001135. [PMID: 30364389 DOI: 10.1136/bmjgh-2018-001135] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
140 Kwara A, Herold JS, Machan JT, Carter EJ. Factors associated with failure to complete isoniazid treatment for latent tuberculosis infection in Rhode Island. Chest 2008;133:862-8. [PMID: 18071014 DOI: 10.1378/chest.07-2024] [Cited by in Crossref: 44] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
141 Cain KP, Garman KN, Laserson KF, Ferrousier-Davis OP, Miranda AG, Wells CD, Haley CA. Moving toward tuberculosis elimination: implementation of statewide targeted tuberculin testing in Tennessee. Am J Respir Crit Care Med 2012;186:273-9. [PMID: 22561962 DOI: 10.1164/rccm.201111-2076OC] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 2.1] [Reference Citation Analysis]
142 Deschildre A, Poirier C, Cadranel J. Dans quelles circonstances et comment traiter une infection tuberculeuse latente ? Revue des Maladies Respiratoires 2004;21:25-34. [DOI: 10.1016/s0761-8425(04)71381-9] [Cited by in Crossref: 8] [Article Influence: 0.5] [Reference Citation Analysis]
143 Dworkin MS, Adams MR, Cohn DL, Davidson AJ, Buskin S, Horwitch C, Morse A, Sackoff J, Thompson M, Wotring L, McCombs SB, Jones JL. Factors that complicate the treatment of tuberculosis in HIV-infected patients. J Acquir Immune Defic Syndr 2005;39:464-70. [PMID: 16010171 DOI: 10.1097/01.qai.0000152400.36723.85] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
144 Diel R, Nienhaus A, Loddenkemper R. Cost-effectiveness of Interferon-γ Release Assay Screening for Latent Tuberculosis Infection Treatment in Germany. Chest 2007;131:1424-34. [DOI: 10.1378/chest.06-2728] [Cited by in Crossref: 53] [Cited by in F6Publishing: 36] [Article Influence: 3.8] [Reference Citation Analysis]
145 Khongphatthanayothin M, Avihingsanon A, Teeratakulpisarn N, Phanuphak N, Buajoom R, Suwanmala P, Phanuphak P. Feasibility and efficacy of isoniazid prophylaxis for latent tuberculosis in HIV-infected clients patients in Thailand. AIDS Res Hum Retroviruses 2012;28:270-5. [PMID: 21899431 DOI: 10.1089/aid.2011.0041] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
146 McMullan GS, Lewis JH. Tuberculosis of the Liver, Biliary Tract, and Pancreas. Microbiol Spectr 2017;5. [PMID: 28233514 DOI: 10.1128/microbiolspec.TNMI7-0025-2016] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
147 Gonzalez-Cao M, Puertolas T, Riveiro M, Muñoz-Couselo E, Ortiz C, Paredes R, Podzamczer D, Manzano JL, Molto J, Revollo B, Carrera C, Mateu L, Fancelli S, Espinosa E, Clotet B, Martinez-Picado J, Cerezuela P, Soria A, Marquez I, Mandala M, Berrocal A; Spanish Melanoma Group (GEM). Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM). J Immunother Cancer 2021;9:e001664. [PMID: 33782108 DOI: 10.1136/jitc-2020-001664] [Reference Citation Analysis]
148 Kasprowicz VO, Churchyard G, Lawn SD, Squire SB, Lalvani A. Diagnosing latent tuberculosis in high-risk individuals: rising to the challenge in high-burden areas. J Infect Dis 2011;204 Suppl 4:S1168-78. [PMID: 21996699 DOI: 10.1093/infdis/jir449] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
149 Kominski GF, Varon SF, Morisky DE, Malotte CK, Ebin VJ, Coly A, Chiao C. Costs and cost-effectiveness of adolescent compliance with treatment for latent tuberculosis infection: results from a randomized trial. J Adolesc Health 2007;40:61-8. [PMID: 17185207 DOI: 10.1016/j.jadohealth.2006.08.012] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
150 Wu SS, Chao CS, Vargas JH, Sharp HL, Martín MG, Mcdiarmid SV, Sinatra FR, Ament ME. Isoniazid-Related Hepatic Failure in Children: A Survey of Liver Transplantation Centers. Transplantation 2007;84:173-9. [DOI: 10.1097/01.tp.0000269104.22502.d2] [Cited by in Crossref: 39] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
151 Lee WM, Senior JR. Recognizing drug-induced liver injury: current problems, possible solutions. Toxicol Pathol. 2005;33:155-164. [PMID: 15805067 DOI: 10.1080/01926230590522356] [Cited by in Crossref: 131] [Cited by in F6Publishing: 103] [Article Influence: 8.2] [Reference Citation Analysis]
152 Gilroy SA, Rogers MAM, Blair DC. Treatment of Latent Tuberculosis Infection in Patients Aged ≥35 Years. Clinical Infectious Diseases 2000;31:826-9. [DOI: 10.1086/314037] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.1] [Reference Citation Analysis]
153 McElroy PD, Ijaz K, Lambert LA, Jereb JA, Iademarco MF, Castro KG, Navin TR. National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection. Clin Infect Dis 2005;41:1125-33. [PMID: 16163632 DOI: 10.1086/444463] [Cited by in Crossref: 45] [Cited by in F6Publishing: 32] [Article Influence: 2.8] [Reference Citation Analysis]
154 Hersh AL, Tosteson AN, von Reyn C. Dual skin testing for latent tuberculosis infection. American Journal of Preventive Medicine 2003;24:254-9. [DOI: 10.1016/s0749-3797(02)00584-6] [Cited by in Crossref: 6] [Article Influence: 0.3] [Reference Citation Analysis]
155 Riestra S, Taxonera C, Carpio D, López-san Román A, Gisbert J, Domènech E. Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre el cribado y tratamiento de la tuberculosis latente en pacientes con enfermedad inflamatoria intestinal. Enfermedad Inflamatoria Intestinal al Día 2015;14:109-19. [DOI: 10.1016/j.eii.2015.09.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
156 Stout JE, Engemann JJ, Cheng AC, Fortenberry ER, Hamilton CD. Safety of 2 Months of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis. Am J Respir Crit Care Med 2003;167:824-7. [DOI: 10.1164/rccm.200209-998oc] [Cited by in Crossref: 57] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
157 Jung BH, Park JI, Lee SG. Urgent Living-Donor Liver Transplantation in a Patient With Concurrent Active Tuberculosis: A Case Report. Transplant Proc. 2018;50:910-914. [PMID: 29661461 DOI: 10.1016/j.transproceed.2018.02.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
158 Zazuli Z, Barliana MI, Mulyani UA, Perwitasari DA, Ng H, Abdulah R. Polymorphism of PXR gene associated with the increased risk of drug-induced liver injury in Indonesian pulmonary tuberculosis patients. J Clin Pharm Ther 2015;40:680-4. [PMID: 26417664 DOI: 10.1111/jcpt.12325] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
159 Wang JY, Liu CH, Hu FC, Chang HC, Liu JL, Chen JM, Yu CJ, Lee LN, Kao JH, Yang PC. Risk factors of hepatitis during anti-tuberculous treatment and implications of hepatitis virus load. J Infect. 2011;62:448-455. [PMID: 21570123 DOI: 10.1016/j.jinf.2011.04.005] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 3.8] [Reference Citation Analysis]
160 Trinh TT, Han DT, Bloss E, Le TH, Vu TT, Mai AH, Nguyen NV, Nguyen LT, Dinh SN, Whitehead S. Implementation and evaluation of an isoniazid preventive therapy pilot program among HIV-infected patients in Vietnam, 2008-2010. Trans R Soc Trop Med Hyg 2015;109:653-9. [PMID: 26385936 DOI: 10.1093/trstmh/trv074] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
161 Kleiner DE. Drugs and Toxins. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 673-779. [DOI: 10.1016/b978-0-7020-6697-9.00012-1] [Cited by in Crossref: 9] [Article Influence: 3.0] [Reference Citation Analysis]
162 Wang JY, Tsai CH, Lee YL, Lee LN, Hsu CL, Chang HC, Chen JM, Hsu CA, Yu CJ, Yang PC. Gender-Dimorphic Impact of PXR Genotype and Haplotype on Hepatotoxicity During Antituberculosis Treatment. Medicine (Baltimore) 2015;94:e982. [PMID: 26091473 DOI: 10.1097/MD.0000000000000982] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
163 Zhang T, Ikejima T, Li L, Wu R, Yuan X, Zhao J, Wang Y, Peng S. Impairment of Mitochondrial Biogenesis and Dynamics Involved in Isoniazid-Induced Apoptosis of HepG2 Cells Was Alleviated by p38 MAPK Pathway. Front Pharmacol 2017;8:753. [PMID: 29123480 DOI: 10.3389/fphar.2017.00753] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
164 Sung YK, Cho SK, Kim D, Won S, Choi CB, Kim TH, Jun JB, Yoo DH, Bae SC. Isoniazid treatment for latent tuberculosis infection is tolerable for rheumatoid arthritis patients receiving tumor necrosis factor inhibitor therapy. Korean J Intern Med 2018;33:1016-24. [PMID: 28288508 DOI: 10.3904/kjim.2016.214] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
165 Tavil B, Gulhan B, Ozcelik U, Cetin M, Tezcan I, Tuncer M, Uckan D. Tuberculin skin test positivity in pediatric allogeneic BMT recipients and donors in Turkey. Pediatric Transplantation 2007;11:414-8. [DOI: 10.1111/j.1399-3046.2007.00679.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
166 Sheen E, Huang RJ, Uribe LA, Nguyen MH. Isoniazid Hepatotoxicity Requiring Liver Transplantation. Dig Dis Sci 2014;59:1370-4. [DOI: 10.1007/s10620-014-3072-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
167 Villanueva-Paz M, Morán L, López-Alcántara N, Freixo C, Andrade RJ, Lucena MI, Cubero FJ. Oxidative Stress in Drug-Induced Liver Injury (DILI): From Mechanisms to Biomarkers for Use in Clinical Practice. Antioxidants (Basel) 2021;10:390. [PMID: 33807700 DOI: 10.3390/antiox10030390] [Reference Citation Analysis]
168 Sanford C. Pre-travel advice: an overview. Primary Care: Clinics in Office Practice 2002;29:767-85. [DOI: 10.1016/s0095-4543(02)00046-5] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
169 Hatzenbuehler LA, Starke JR. Treatment of tuberculosis infection in children. Expert Rev Anti Infect Ther 2018;16:695-708. [PMID: 30132364 DOI: 10.1080/14787210.2018.1513324] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
170 Thrupp L, Bradley S, Smith P, Simor A, Gantz N, Crossley K, Loeb M, Strausbaugh L, Nicolle L; SHEA Long-Term-Care Committee. Tuberculosis prevention and control in long-term-care facilities for older adults. Infect Control Hosp Epidemiol 2004;25:1097-108. [PMID: 15636299 DOI: 10.1086/502350] [Cited by in Crossref: 33] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
171 Marschall H, Wagner M, Zollner G, Trauner M. Clinical Hepatotoxicity. Regulation and Treatment with Inducers of Transport and Cofactors. Mol Pharmaceutics 2007;4:895-910. [DOI: 10.1021/mp060133c] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
172 Yew WW, Leung CC. Antituberculosis drugs and hepatotoxicity. Respirology. 2006;11:699-707. [PMID: 17052297 DOI: 10.1111/j.1440-1843.2006.00941.x] [Cited by in Crossref: 143] [Cited by in F6Publishing: 112] [Article Influence: 10.2] [Reference Citation Analysis]
173 Xia YY, Hu DY, Liu FY, Wang XM, Yuan YL, Tu DH, Chen YX, Zhou L, Zhu LZ, Gao WW. Design of the anti-tuberculosis drugs induced adverse reactions in China National Tuberculosis Prevention and Control Scheme Study (ADACS). BMC Public Health. 2010;10:267. [PMID: 20492672 DOI: 10.1186/1471-2458-10-267] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
174 Jasmer RM, Daley CL. Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection: Is It Safe? Am J Respir Crit Care Med 2003;167:809-10. [DOI: 10.1164/rccm.2301002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
175 Orenstein R, Tsogas N. Looking Beyond Highly Active Antiretroviral Therapy: Drug-Related Hepatotoxicity in Patients with Human Immunodeficiency Virus Infection. Pharmacotherapy 2002;22:1468-78. [DOI: 10.1592/phco.22.16.1468.33702] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
176 Cybulski DJ, White BK. Fatal Isoniazid Hepatotoxicity in the Deployed Environment. Mil Med 2021;186:619-22. [PMID: 33128555 DOI: 10.1093/milmed/usaa414] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
177 Bray M, Poulain C, Dougados M, Gossec L. Frequency and tolerance of antituberculosis treatment according to national guidelines for prevention of risk of tuberculosis due to tumor necrosis factor blocker treatment. Joint Bone Spine 2010;77:135-41. [DOI: 10.1016/j.jbspin.2009.10.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
178 Kucharzik T, Ellul P, Greuter T, Rahier JF, Verstockt B, Abreu C, Albuquerque A, Allocca M, Esteve M, Farraye FA, Gordon H, Karmiris K, Kopylov U, Kirchgesner J, MacMahon E, Magro F, Maaser C, de Ridder L, Taxonera C, Toruner M, Tremblay L, Scharl M, Viget N, Zabana Y, Vavricka S. ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease. J Crohns Colitis 2021;15:879-913. [PMID: 33730753 DOI: 10.1093/ecco-jcc/jjab052] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
179 Akolo C, Bada F, Okpokoro E, Nwanne O, Iziduh S, Usoroh E, Ali T, Ibeziako V, Oladimeji O, Odo M. Debunking the myths perpetuating low implementation of isoniazid preventive therapy amongst human immunodeficiency virus-infected persons. World J Virol 2015;4:105-12. [PMID: 25964875 DOI: 10.5501/wjv.v4.i2.105] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
180 Papanikolaou PN, Christidi GD, Ioannidis JP. Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies. CMAJ 2006;174:635-41. [PMID: 16505459 DOI: 10.1503/cmaj.050873] [Cited by in Crossref: 141] [Cited by in F6Publishing: 122] [Article Influence: 9.4] [Reference Citation Analysis]
181 Burman W, Reves R. Hepatotoxicity from Rifampin Plus Pyrazinamide: Lessons for Policymakers and Messages for Care Providers. Am J Respir Crit Care Med 2001;164:1112-3. [DOI: 10.1164/ajrccm.164.7.2109052] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
182 Hirten R, Sultan K, Thomas A, Bernstein DE. Hepatic manifestations of non-steroidal inflammatory bowel disease therapy. World J Hepatol 2015;7:2716-28. [PMID: 26644815 DOI: 10.4254/wjh.v7.i27.2716] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
183 Watkins PB, Seligman PJ, Pears JS, Avigan MI, Senior JR. Using controlled clinical trials to learn more about acute drug-induced liver injury. Hepatology 2008;48:1680-9. [PMID: 18853438 DOI: 10.1002/hep.22633] [Cited by in Crossref: 81] [Cited by in F6Publishing: 66] [Article Influence: 6.2] [Reference Citation Analysis]
184 McClure JJ, Li X, Chou CJ. Advances and Challenges of HDAC Inhibitors in Cancer Therapeutics. Adv Cancer Res 2018;138:183-211. [PMID: 29551127 DOI: 10.1016/bs.acr.2018.02.006] [Cited by in Crossref: 77] [Cited by in F6Publishing: 61] [Article Influence: 25.7] [Reference Citation Analysis]
185 Stout JE. Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection. Expert Opinion on Drug Safety 2005;3:187-98. [DOI: 10.1517/14740338.3.3.187] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
186 Yamada S, Richardson K, Tang M, Halaschek-Wiener J, Cook VJ, Fitzgerald JM, Elwood K, Marra F, Brooks-Wilson A. Genetic variation in carboxylesterase genes and susceptibility to isoniazid-induced hepatotoxicity. Pharmacogenomics J 2010;10:524-36. [PMID: 20195289 DOI: 10.1038/tpj.2010.5] [Cited by in Crossref: 40] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
187 Noh CS, Kim HI, Choi H, Kim Y, Kim CH, Choi JH, Hyun IG, Baek MS. Completion rate of latent tuberculosis infection treatment in patients aged 65 years and older. Respir Med 2019;157:52-8. [PMID: 31522030 DOI: 10.1016/j.rmed.2019.09.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
188 Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl. 2004;10:1018-1023. [PMID: 15390328 DOI: 10.1002/lt.20204] [Cited by in Crossref: 311] [Cited by in F6Publishing: 249] [Article Influence: 18.3] [Reference Citation Analysis]
189 Liu F, Jiao AX, Wu XR, Zhao W, Yin QQ, Qi H, Jiao WW, Xiao J, Sun L, Shen C, Tian JL, Shen D, Jacqz-Aigrain E, Shen AD. Impact of glutathione S-transferase M1 and T1 on anti-tuberculosis drug-induced hepatotoxicity in Chinese pediatric patients. PLoS One 2014;9:e115410. [PMID: 25525805 DOI: 10.1371/journal.pone.0115410] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
190 Pease C, Hutton B, Yazdi F, Wolfe D, Hamel C, Barbeau P, Skidmore B, Alvarez GG. A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection. Pharmacoepidemiol Drug Saf 2018;27:557-66. [DOI: 10.1002/pds.4423] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 5.3] [Reference Citation Analysis]
191 Cohn DL. Treatment of Latent Tuberculosis Infection: Renewed Opportunity for Tuberculosis Control. Clinical Infectious Diseases 2000;31:120-4. [DOI: 10.1086/313891] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
192 Yue J, Peng R, Chen J, Liu Y, Dong G. Effects of rifampin on CYP2E1-dependent hepatotoxicity of isoniazid in rats. Pharmacological Research 2009;59:112-9. [DOI: 10.1016/j.phrs.2008.10.006] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
193 Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov. 2005;4:489-499. [PMID: 15931258 DOI: 10.1038/nrd1750] [Cited by in Crossref: 738] [Cited by in F6Publishing: 582] [Article Influence: 46.1] [Reference Citation Analysis]
194 Schenker S, Martin RR, Hoyumpa AM. Antecedent liver disease and drug toxicity. J Hepatol. 1999;31:1098-1105. [PMID: 10604586 DOI: 10.1016/s0168-8278(99)80325-0] [Cited by in Crossref: 43] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
195 Porco TC, Lewis B, Marseille E, Grinsdale J, Flood JM, Royce SE. Cost-effectiveness of tuberculosis evaluation and treatment of newly-arrived immigrants. BMC Public Health 2006;6:157. [PMID: 16784541 DOI: 10.1186/1471-2458-6-157] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
196 Sabaté M, Ibáñez L, Pérez E, Vidal X, Buti M, Xiol X, Mas A, Guarner C, Forné M, Solà R, Castellote J, Rigau J, Laporte J. Risk of acute liver injury associated with the use of drugs: a multicentre population survey: DRUG-INDUCED LIVER DISEASE. Alimentary Pharmacology & Therapeutics 2007;25:1401-9. [DOI: 10.1111/j.1365-2036.2007.03338.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 37] [Article Influence: 3.4] [Reference Citation Analysis]
197 Sadaphal P, Astemborski J, Graham NM, Sheely L, Bonds M, Madison A, Vlahov D, Thomas DL, Sterling TR. Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis. Clin Infect Dis. 2001;33:1687-1691. [PMID: 11641824 DOI: 10.1086/323896] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 2.0] [Reference Citation Analysis]
198 Shehu AI, Ma X, Venkataramanan R. Mechanisms of Drug-Induced Hepatotoxicity. Clin Liver Dis. 2017;21:35-54. [PMID: 27842774 DOI: 10.1016/j.cld.2016.08.002] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 9.3] [Reference Citation Analysis]
199 Regev A. How to avoid being surprised by hepatotoxicity at the final stages of drug development and approval. Clin Liver Dis. 2013;17:749-767, xi. [PMID: 24099029 DOI: 10.1016/j.cld.2013.07.014] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
200 Senior JR. How can 'Hy's law' help the clinician? Pharmacoepidemiol Drug Saf 2006;15:235-9. [PMID: 16552792 DOI: 10.1002/pds.1210] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
201 Waiser J, Schötschel R, Budde K, Neumayer H. Reactivation of tuberculosis after conversion from azathioprine to mycophenolate mofetil 16 years after renal transplantation. American Journal of Kidney Diseases 2000;35:e12.1-5. [DOI: 10.1016/s0272-6386(00)70224-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
202 Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, Chaisson LH, Chaisson RE, Daley CL, Grzemska M, Higashi JM, Ho CS, Hopewell PC, Keshavjee SA, Lienhardt C, Menzies R, Merrifield C, Narita M, O'Brien R, Peloquin CA, Raftery A, Saukkonen J, Schaaf HS, Sotgiu G, Starke JR, Migliori GB, Vernon A. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 2016;63:e147-95. [PMID: 27516382 DOI: 10.1093/cid/ciw376] [Cited by in Crossref: 462] [Cited by in F6Publishing: 304] [Article Influence: 92.4] [Reference Citation Analysis]
203 Bhilare NV, Dhaneshwar SS, Mahadik KR. Amelioration of hepatotoxicity by biocleavable aminothiol chimeras of isoniazid: Design, synthesis, kinetics and pharmacological evaluation. World J Hepatol 2018;10:496-508. [PMID: 30079136 DOI: 10.4254/wjh.v10.i7.496] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
204 Haley CA. Treatment of Latent Tuberculosis Infection. Microbiol Spectr 2017;5. [PMID: 28409555 DOI: 10.1128/microbiolspec.TNMI7-0039-2016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
205 Frydenberg AR, Graham SM. Toxicity of first-line drugs for treatment of tuberculosis in children: review: Toxicity of first-line drugs for treatment of TB in children. Tropical Medicine & International Health 2009;14:1329-37. [DOI: 10.1111/j.1365-3156.2009.02375.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 33] [Article Influence: 3.9] [Reference Citation Analysis]
206 Senior JR. What is idiosyncratic hepatotoxicity? What is it not? Hepatology 2008;47:1813-5. [PMID: 18508312 DOI: 10.1002/hep.22332] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
207 Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA, Gordin FM, Nunes D, Strader DB. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174:935-952. [PMID: 17021358 DOI: 10.1164/rccm.200510-1666st] [Cited by in Crossref: 597] [Cited by in F6Publishing: 198] [Article Influence: 39.8] [Reference Citation Analysis]
208 Bieber J, Kavanaugh A. Consideration of the risk and treatment of tuberculosis in patients who have rheumatoid arthritis and receive biologic treatments. Rheumatic Disease Clinics of North America 2004;30:257-70. [DOI: 10.1016/j.rdc.2004.01.003] [Cited by in Crossref: 43] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
209 Wyndham-Thomas C, Dirix V, Goffard JC, Henrard S, Wanlin M, Callens S, Mascart F, Van Vooren JP. 2018 Belgian guidelines for the screening for latent tuberculosis in HIV-infected patients. Acta Clin Belg 2019;74:242-51. [PMID: 30036162 DOI: 10.1080/17843286.2018.1494669] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
210 Lewis JH, Kleiner DE. Hepatic injury due to drugs, herbal compounds, chemicals and toxins. MacSween's Pathology of the Liver. Elsevier; 2012. pp. 645-760. [DOI: 10.1016/b978-0-7020-3398-8.00013-1] [Cited by in Crossref: 11] [Article Influence: 1.2] [Reference Citation Analysis]
211 Rahier JF, Ben-Horin S, Chowers Y, Conlon C, De Munter P, D’Haens G, Domènech E, Eliakim R, Eser A, Frater J. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2009;3:47-91. [PMID: 21172250 DOI: 10.1016/j.crohns.2009.02.010] [Cited by in Crossref: 353] [Cited by in F6Publishing: 292] [Article Influence: 29.4] [Reference Citation Analysis]
212 Murray KF, Hadzic N, Wirth S, Bassett M, Kelly D. Drug-related hepatotoxicity and acute liver failure. J Pediatr Gastroenterol Nutr. 2008;47:395-405. [PMID: 18852631 DOI: 10.1097/mpg.0b013e3181709464] [Cited by in Crossref: 83] [Cited by in F6Publishing: 22] [Article Influence: 6.9] [Reference Citation Analysis]
213 Lobue PA, Moser KS. Use of Isoniazid for Latent Tuberculosis Infection in a Public Health Clinic. Am J Respir Crit Care Med 2003;168:443-7. [DOI: 10.1164/rccm.200303-390oc] [Cited by in Crossref: 146] [Cited by in F6Publishing: 48] [Article Influence: 8.1] [Reference Citation Analysis]
214 Gomes VF, Andersen A, Lemvik G, Wejse C, Oliveira I, Vieira FJ, Carlos LJ, Vieira Cda S, Aaby P, Gustafson P. Impact of isoniazid preventive therapy on mortality among children less than 5 years old following exposure to tuberculosis at home in Guinea-Bissau: a prospective cohort study. BMJ Open 2013;3:e001545. [PMID: 23535699 DOI: 10.1136/bmjopen-2012-001545] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
215 Senior JR. Monitoring for hepatotoxicity: what is the predictive value of liver "function" tests? Clin Pharmacol Ther 2009;85:331-4. [PMID: 19129750 DOI: 10.1038/clpt.2008.262] [Cited by in Crossref: 68] [Cited by in F6Publishing: 48] [Article Influence: 5.7] [Reference Citation Analysis]
216 Lynn Johnston B, Conly JM. Re-examining treatment of latent tuberculosis infection. Can J Infect Dis 2001;12:211-4. [PMID: 18159342 DOI: 10.1155/2001/616419] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
217 Tshikuka Mulumba JG, Atua Matindii B, Kilauzi AL, Mengema B, Mafuta J, Eloko Eya Matangelo G, Mukongo Bulaïmu-Lukeba A, Jerry IL. Severity of outcomes associated to types of HIV coinfection with TB and malaria in a setting where the three pandemics overlap. J Community Health 2012;37:1234-8. [PMID: 22477668 DOI: 10.1007/s10900-012-9559-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
218 Chalasani N, Reddy KRK, Fontana RJ, Barnhart H, Gu J, Hayashi PH, Ahmad J, Stolz A, Navarro V, Hoofnagle JH. Idiosyncratic Drug Induced Liver Injury in African-Americans Is Associated With Greater Morbidity and Mortality Compared to Caucasians.Am J Gastroenterol. 2017;112:1382-1388. [PMID: 28762375 DOI: 10.1038/ajg.2017.215] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
219 Ahmad S. New approaches in the diagnosis and treatment of latent tuberculosis infection. Respir Res 2010;11:169. [PMID: 21126375 DOI: 10.1186/1465-9921-11-169] [Cited by in Crossref: 40] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
220 Gülbay BE, Gürkan OU, Yildiz OA, Onen ZP, Erkekol FO, Baççioğlu A, Acican T. Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis. Respir Med 2006;100:1834-42. [PMID: 16517138 DOI: 10.1016/j.rmed.2006.01.014] [Cited by in Crossref: 78] [Cited by in F6Publishing: 51] [Article Influence: 5.2] [Reference Citation Analysis]
221 Chitturi S, Farrell GC. Drug-Induced Liver Disease. In: Schiff ER, Maddrey WC, Sorrell MF, editors. Schiff's Diseases of the Liver. Oxford: Wiley-Blackwell; 2011. pp. 703-83. [DOI: 10.1002/9781119950509.ch27] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
222 Perriot J, Chambonnet E, Eschalier A. [Managing the adverse events of antitubercular agents]. Rev Mal Respir. 2011;28:542-555. [PMID: 21549908 DOI: 10.1016/j.rmr.2010.10.034] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
223 Fountain FF, Tolley E, Chrisman CR, Self TH. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest. 2005;128:116-123. [PMID: 16002924 DOI: 10.1378/chest.128.1.116] [Cited by in Crossref: 165] [Cited by in F6Publishing: 122] [Article Influence: 10.3] [Reference Citation Analysis]
224 Priest DH, Vossel LF, Sherfy EA, Hoy DP, Haley CA. Use of Intermittent Rifampin and Pyrazinamide Therapy for Latent Tuberculosis Infection in a Targeted Tuberculin Testing Program. Clinical Infectious Diseases 2004;39:1764-71. [DOI: 10.1086/425610] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
225 Chee CB, Sester M, Zhang W, Lange C. Diagnosis and treatment of latent infection with Mycobacterium tuberculosis: LTBI diagnosis and treatment. Respirology 2013;18:205-16. [DOI: 10.1111/resp.12002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
226 Sotgiu G, Matteelli A, Getahun H, Girardi E, Sañé Schepisi M, Centis R, Migliori GB. Monitoring toxicity in individuals receiving treatment for latent tuberculosis infection: a systematic review versus expert opinion. Eur Respir J 2015;45:1170-3. [PMID: 25700378 DOI: 10.1183/09031936.00216814] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
227 Forget EJ, Menzies D. Adverse reactions to first-line antituberculosis drugs. Expert Opin Drug Saf. 2006;5:231-249. [PMID: 16503745 DOI: 10.1517/14740338.5.2.231] [Cited by in Crossref: 127] [Cited by in F6Publishing: 91] [Article Influence: 8.5] [Reference Citation Analysis]
228 Parikh ND, Levitsky J. Hepatotoxicity and drug interactions in liver transplant candidates and recipients. Clin Liver Dis 2013;17:737-47, x-xi. [PMID: 24099028 DOI: 10.1016/j.cld.2013.07.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
229 Li AA, Dibba P, Cholankeril G, Kim D, Ahmed A. Case Report of Isoniazid-Related Acute Liver Failure Requiring Liver Transplantation. Diseases 2018;6:E40. [PMID: 29783726 DOI: 10.3390/diseases6020040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
230 Patel PA, Voigt MD. Prevalence and interaction of hepatitis B and latent tuberculosis in Vietnamese immigrants to the United States. Am J Gastroenterol. 2002;97:1198-1203. [PMID: 12014728 DOI: 10.1111/j.1572-0241.2002.05704.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 2.4] [Reference Citation Analysis]
231 Getahun H, Granich R, Sculier D, Gunneberg C, Blanc L, Nunn P, Raviglione M. Implementation of isoniazid preventive therapy for people living with HIV worldwide: barriers and solutions. AIDS. 2010;24 Suppl 5:S57-S65. [PMID: 21079430 DOI: 10.1097/01.aids.0000391023.03037.1f] [Cited by in Crossref: 52] [Cited by in F6Publishing: 58] [Article Influence: 5.2] [Reference Citation Analysis]
232 Yue J, Dong G, He C, Chen J, Liu Y, Peng R. Protective effects of thiopronin against isoniazid-induced hepatotoxicity in rats. Toxicology 2009;264:185-91. [DOI: 10.1016/j.tox.2009.08.006] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
233 Loureiro RB, Maciel ELN, Caetano R, Peres RL, Fregona G, Golub JE, Braga JU. Cost-effectiveness of QuantiFERON-TB Gold In-Tube versus tuberculin skin test for diagnosis and treatment of Latent Tuberculosis Infection in primary health care workers in Brazil. PLoS One 2019;14:e0225197. [PMID: 31725786 DOI: 10.1371/journal.pone.0225197] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
234 Agal S, Baijal R, Pramanik S, Patel N, Gupte P, Kamani P, Amarapurkar D. Monitoring and management of antituberculosis drug induced hepatotoxicity. J Gastroenterol Hepatol 2005;20:1745-52. [DOI: 10.1111/j.1440-1746.2005.04048.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 43] [Article Influence: 3.3] [Reference Citation Analysis]
235 Cojutti P, Giangreco M, Isola M, Pea F. Limited sampling strategies for determining the area under the plasma concentration–time curve for isoniazid might be a valuable approach for optimizing treatment in adult patients with tuberculosis. International Journal of Antimicrobial Agents 2017;50:23-8. [DOI: 10.1016/j.ijantimicag.2017.01.036] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]